P
ABVX

&Partners’s Abivax ABVX Stock Holding History

&Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Sell
1,854
-360
-16% -$42.6K ﹤0.01% 2234
2025
Q4 		$299K Buy
+2,214
New +$242K ﹤0.01% 1915

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

&Partners's ABVX Position: Q1 2026 in Review

&Partners reduced its Abivax (ABVX) stake by 16% in Q1 2026, selling an estimated $42.6K and leaving 1,854 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

&Partners first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $299K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • &Partners held 1,854 shares of Abivax worth $206K as of Q1 2026.
  • &Partners sold 360 Abivax shares in Q1 2026, an estimated $42.6K.
  • Abivax made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2234 holding.
  • &Partners first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
  • &Partners's Abivax position peaked at $299K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.